Antipsychotics and the risk of death in the elderly: An instrumental variable analysis using two preference based instruments

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 7, 2010, Pages 699-707

  Pratt, Nicole ^a   Roughead, Elizabeth E ^b   Ryan, Philip ^a   Salter, Amy ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Antipsychotics; Confounding; Death; Instrumental variable; Mortality

Indexed keywords

ACETYLSALICYLIC ACID; AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERICIAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TRIFLUOPERAZINE; ZIPRASIDONE;

AGED; ARTICLE; CONTROLLED STUDY; DRUG FATALITY; FEMALE; GERIATRIC CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NURSING CARE; NURSING HOME; PRESCRIPTION; PRIORITY JOURNAL; AUSTRALIA; CAUSE OF DEATH; CLINICAL PRACTICE; COMPARATIVE STUDY; FACTUAL DATABASE; PHARMACOEPIDEMIOLOGY; PROCEDURES; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; VETERAN;

AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; AUSTRALIA; CAUSE OF DEATH; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; NURSING HOMES; PHARMACOEPIDEMIOLOGY; PHYSICIAN'S PRACTICE PATTERNS; VETERANS;

EID: 77955606293     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1942     Document Type: Article

References (43)

1. Australian Government Department of Health and Ageing. Australian Statistics on Medicines. Australian Government Department of Health and Ageing, Canberra, 2007.
2. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006; 1: CD003476.
3. Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev 2002; 2: CD002852.
4. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006; 355(15): 1525-1538.
5. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294(15): 1934-1943.
6. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007; 146(11): 775-786.
7. Gill SS, Seitz DP. Association of antipsychotics with mortality among elderly patients with dementia. Am J Geriatr Psychiatry 2007; 15(11): 983-984 (author reply 984-985).
8. Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009; 8(2): 151-157.
9. Hugenholtz GW, Heerdink ER, van Staa TP, Nolen WA, Egberts AC. Risk of hip/femur fractures in patients using antipsychotics. Bone 2005; 37(6): 864-870.
10. Kolanowski A, Fick D, Waller JL, Ahern F. Outcomes of antipsychotic drug use in community-dwelling elders with dementia. Arch Psychiatr Nurs 2006; 20(5): 217-225.
11. Liperoti R, Onder G, Lapane KL, et al. Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case-control study. J Clin Psychiatry 2007; 68(6): 929-934.
12. Normand SL, Sykora K, Li P, Mamdani M, Rochon PA, Anderson GM. Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding. Br Med J 2005; 330(7498): 1021-1023.
13. Knol W, van Marum RJ, Jansen PA, Souverein PC, Schobben AF, Egberts AC. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc 2008; 56(4): 661-666.
14. Wada H, Nakajoh K, Satoh-Nakagawa T, et al. Risk factors of aspiration pneumonia in Alzheimer's disease patients. Gerontology 2001; 47(5): 271-276.
15. Hollis J, Forrester L, Brodaty H, Touyz S, Cumming R, Grayson D. Risk of death associated with antipsychotic drug dispensing in residential aged care facilities. Aust N Z J Psychiatry 2007; 41(9): 751-758.
16. Hollis J, Grayson D, Forrester L, Brodaty H, Touyz S, Cumming R. Antipsychotic medication dispensing and risk of death in veterans and war widows 65 years and older. Am J Geriatr Psychiatry 2007; 15(11): 932-941.
17. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007; 176(5): 627-632.
18. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005; 353(22): 2335-2341.
19. Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA 2007; 297(3): 278-285.
20. Brookhart MA, Wang PS, Solomon DH, Schneeweiss S. Instrumental variable analysis of secondary pharmacoepidemiologic data. Epidemiology 2006; 17(4): 373-374.
21. Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol 2000; 29(4): 722-729.
22. Martens EP, Pestman WR, de Boer A, Belitser SV, Klungel OH. Instrumental variables: application and limitations. Epidemiology 2006; 17(3): 260-267.
23. Hernan MA, Robins JM. Instruments for causal inference: an epidemiologist's dream? Epidemiology 2006; 17(4): 360-372.
24. Rassen JA, Brookhart MA, Glynn RJ, Mittleman MA, Schneeweiss S. Instrumental variables II: instrumental variable application-in 25 variations, the physician prescribing preference generally was strong and reduced covariate imbalance. J Clin Epidemiol 2009; 62(12): 1233-1241.
25. Liperoti R, Mor V, Lapane KL, Pedone C, Gambassi G, Bernabei R. The use of atypical antipsychotics in nursing homes. J Clin Psychiatry 2003; 64(9): 1106-1112.
26. World Health Organization Collaborating Centre for Drug Statistics Methodology. Anatomical therapeutic chemical code classification index with defined daily doses. Available at: http://www.whocc.no/atcddd/
27. Australian Government Department of Health and Ageing. Schedule of pharmaceutical benefits. PBS for health professionals. Available at: http://www.pbs.gov.au/html/healthpro/home
28. The International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Australian Modification (ICD-10-AM), 6th edn, National Centre for Classification in Health: Sydney, 2005.
29. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol 2005; 162(3): 199-200.
30. Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55.
31. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol 2006; 163(12): 1149-1156.
32. Brookhart MA, Rassen JA, Wang PS, Dormuth C, Mogun H, Schneeweiss S. Evaluating the validity of an instrumental variable study of neuroleptics: can between-physician differences in prescribing patterns be used to estimate treatment effects? Med Care 2007; 45 (10 Suppl. 2): S116-S122.
33. Wang PS, Schneeweiss S, Setoguchi S, et al. Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications. J Clin Psychopharmacol 2007; 27(6): 707-710.
34. Ionescu-Ittu R, Delaney JA, Abrahamowicz M. Bias-variance trade-off in pharmacoepidemiological studies using physician-preference-based instrumental variables: a simulation study. Pharmacoepidemiol Drug Saf 2009; 18(7): 562-571.
35. Schneeweiss S, Setoguchi S, Brookhart MA, Kaci L, Wang PS. Assessing residual confounding of the association between antipsychotic medications and risk of death using survey data. CNS Drugs 2009; 23(2): 171-180.
36. Setoguchi S, Wang PS, Alan Brookhart M, Canning CF, Kaci L, Schneeweiss S. Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. J Am Geriatr Soc 2008; 56(9): 1644-1650.
37. Brodaty H, Ames D, Snowdon J, et al. Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial. Int J Geriatr Psychiatry 2005; 20(12): 1153-1157.
38. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53(5): 946-955.
39. Katz I, de Deyn PP, Mintzer J, Greenspan A, Zhu Y, Brodaty H. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry 2007; 22(5): 475-484. (Pubitemid 46831692)
40. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999; 60(2): 107-115.
41. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006; 14(3): 191-210.
42. Sultzer DL, Davis SM, Tariot PN, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 2008; 165(7): 844-854.
43. Jick H, Garcia Rodriguez LA, Perez-Gutthann S. Principles of epidemiological research on adverse and beneficial drug effects. Lancet 1998; 352(9142): 1767-1770.